There are currently 213 clinical trials in Torrance, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Harbor-UCLA Medical Center, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance Memorial Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma
NCT05280366
Recruiting
A study of the Streamline Surgical System versus competitor
Gender:
All
Ages:
22 years and above
Trial Updated:
04/11/2024
Locations: Wolstan and Goldberg Eye Associates, Torrance, California
Conditions: Open Angle Glaucoma
Register for Updates
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
NCT03418961
Recruiting
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: City of Hope South Bay, Torrance, California
Conditions: Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Register for Updates
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
NCT04499248
Recruiting
This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Premiere Practice Management LLC /ID# 235957, Torrance, California +1 locations
Conditions: Open-angle Glaucoma, Ocular Hypertension
Register for Updates
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
NCT02138734
Recruiting
This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG naïve patients with high-grade NMIBC.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Skyline Urology, Torrance, California
Conditions: Non-muscle Invasive Bladder Cancer
Register for Updates
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
NCT05859698
Recruiting
This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who are receiving valbenazine for up to 24 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/10/2024
Locations: Neurocrine Clinical Site, Torrance, California
Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Register for Updates
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
NCT03970343
Recruiting
The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Torrance Memorial Medical Center, Torrance, California
Conditions: Heart Failure
Register for Updates
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807
Recruiting
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observa... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Torrance Memorial Physician Network - Cancer Care, Torrance, California
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
Neuropsychological and Behavioral Testing in Younger Patients With Cancer
NCT00772200
Recruiting
This research trial studies neuropsychological (learning, remembering or thinking) and behavioral outcomes in children and adolescents with cancer by collecting information over time from a series of tests.
Gender:
All
Ages:
1 month and above
Trial Updated:
04/05/2024
Locations: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California
Conditions: Childhood Malignant Neoplasm
Register for Updates
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
NCT05360446
Recruiting
CKJX839D12303 is a research study to determine if the study treatment, called inclisiran, in comparison to placebo taken in addition to statin medication can effectively reduce the total amount of plaque formed in the heart's vessels as measured by coronary computed tomography angiography (CCTA) from baseline to month 24. This study is being conducted in eligible participants with a diagnosis of non-obstructive coronary artery disease (NOCAD), where the coronary arteries are blocked less than 50... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/04/2024
Locations: Lundquist Inst BioMed at Harbor UCLA Medical Center, Torrance, California
Conditions: Coronary Artery Disease
Register for Updates
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
NCT05401110
Recruiting
The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limiting toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of objec... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Cedars-Sinai Cancer at Hunt Cancer Center - TMPNCC, Torrance, California
Conditions: Non Small Cell Lung Cancer, Lung Cancer
Register for Updates
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
NCT05184764
Recruiting
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to Best Available Antibiotic Therapy Alone for the Treatment of Adults With Bacteremia Due to Staphylococcus aureus
Gender:
All
Ages:
18 years and above
Trial Updated:
03/29/2024
Locations: Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance, California
Conditions: Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Register for Updates
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
NCT04757610
Recruiting
A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
Gender:
All
Ages:
50 years and above
Trial Updated:
03/26/2024
Locations: ShORe Investigational Site, Torrance, California
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates